• Active, not recruiting

NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in NDMM Myeloma

Updated: Jun 22

ECOG-E1A06

ECOG-ACRIN Cancer Research Group


NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma


ECOG-E1A06


Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma


This randomized phase III trial studies melphalan and prednisone with thalidomide to see how well it works compared to melphalan and prednisone together with lenalidomide in treating patients with newly diagnosed multiple myeloma. Drugs used in chemotherapy, such as melphalan and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Thalidomide and lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. It is not yet known whether melphalan and prednisone are more effective when given together with thalidomide or lenalidomide in treating multiple myeloma.


Sponsor

National Cancer Institute (NCI)


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT00602641

Official Title: An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy

First Posted : January 28, 2008


https://clinicaltrials.gov/ct2/show/NCT00602641

 

Thalidomide : National Cancer Institute

Thalidomide : MedlinePlus Drug Information

 

Other: Laboratory Biomarker Analysis

Drug: Lenalidomide

Drug: Melphalan

Drug: Prednisone

Other: Quality-of-Life Assessment

Drug: Thalidomide

 

Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma

Blood; 2015

Use of MPT-T or mPR-R in elderly patients with untreated MM demonstrates no statistical or clinically relevant differences in response rates, PFS, and OS; however, quality of life at end of induction was improved and lower toxicity reported with mPR-R. This trial was registered at www.clinicaltrials.gov


https://pubmed.ncbi.nlm.nih.gov/26157076/

 

Locations

United States, Alabama

United States, Arizona

United States, Arkansas

United States, California

United States, Colorado

United States, Connecticut

United States, District of Columbia

United States, Florida

United States, Georgia

United States, Illinois

United States, Indiana

United States, Iowa

United States, Kansas

United States, Kentucky

United States, Louisiana

United States, Maine

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, Mississippi

United States, Missouri

United States, Montana

United States, Nebraska

United States, Nevada

United States, New Jersey

United States, New York

United States, North Carolina

United States, North Dakota

United States, Ohio

United States, Oklahoma

United States, Oregon

United States, Pennsylvania

United States, South Dakota

United States, Tennessee

United States, Texas

United States, Virginia

United States, Washington

United States, West Virginia

United States, Wisconsin

United States, Wyoming

Asia

Israel





Posts Archive